AKBA vs MLYS
AKBA: A biopharmaceutical company specialized in kidney disease therapeutics with a commercial portfolio for anemia and mineral metabolism and a pipeline of rare disease assets. MLYS: Mineralys is a clinical-stage biopharmaceutical company pursuing FDA approval of lorundrostat, a selective aldosterone synthase inhibitor targeting resistant hypertension and related cardiorenal diseases.
Side-by-side fundamentals
| Metric | AKBA | MLYS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.26 | $27.01 | |
| Market cap as of 2026-07-23 | $349M | $2.4B | |
| Net margin as of 2026-07-23 | -8.8% | n/a | |
| Gross margin as of 2026-07-23 | +79.3% | n/a | |
| Operating margin as of 2026-07-23 | +2.3% | n/a | |
| ROE as of 2026-07-23 | -62.7% | -27.9% | MLYS higher |
| ROA as of 2026-07-23 | -5.7% | -27.0% | AKBA higher |
| Debt / equity as of 2026-07-23 | 7.09 | 0.00 | MLYS lower |
| Revenue growth (YoY) as of 2026-07-23 | +25.7% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -6.9% | n/a | |
| Beta as of 2026-07-23 | 0.26 | 0.59 | |
| 1-year return as of 2026-07-22 close | -67.3% | +102.1% | MLYS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.